



Pipeline

	Product	Potential Indications	Preclinical	Phase 1	Phase 2	Phase 3
	NGM282 FGFR19 Analog	NASH				
	NGM313 FGFR1c/KLB Agonistic Antibody	NASH, Type 2 Diabetes				
	NGM120 GFGRAL Antagonistic Antibody	Cancer Anorexia / Cachexia Syndrome				
	NGM217 Undisclosed	Diabetes				
	NGM621 Undisclosed	Dry Age-Related Macular Degeneration				
	NGM386 GDF15 Analog	Obesity				
	NGM395 GDF15 Analog	Obesity				